FluoGuide AS
96X
Company Profile
Business description
FluoGuide AS is a clinical-stage biotechnology company focused on developing drugs that maximize surgical outcomes by making cancer fluorescent. Its technology includes uPAR, which is part of a proteolytic system, and FG001, a product injected into the patient's vein prior to surgery.
Contact
Titanhus, Titangade 9-13
CopenhagenDK-2200
DNKT: +45 31226660
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Tesla: Shares fall as deliveries come in below consensus
Long-term growth less reliant on auto sales.
stocks
Will Australia’s dwindling fuel supplies impact this share?
Australia’s petrol reserves have dropped from 60 to 35 days.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,893.70 | 31.80 | -0.36% |
| CAC 40 | 7,962.39 | 0.00 | 0.00% |
| DAX 40 | 23,168.08 | 130.81 | -0.56% |
| Dow JONES (US) | 46,669.88 | 165.21 | 0.36% |
| FTSE 100 | 10,436.29 | 71.50 | 0.69% |
| HKSE | 25,116.53 | 177.50 | -0.70% |
| NASDAQ | 21,996.34 | 117.16 | 0.54% |
| Nikkei 225 | 53,441.05 | 27.37 | 0.05% |
| NZX 50 Index | 13,069.66 | 167.51 | 1.30% |
| S&P 500 | 6,611.83 | 29.14 | 0.44% |
| S&P/ASX 200 | 8,701.80 | 28.50 | -0.33% |
| SSE Composite Index | 3,919.29 | 29.27 | -0.74% |